Gold KA, Neskey M, William WN. The role of systemic treatment before, during, and after definitive treatment. Otolaryngol Clin N Am. 2013;46:645–56.
Kelly CG. Chemotherapy: United Kingdom National multidisciplinary guidelines. J Laryngol Otol. 2016;130(Suppl 2):S71–4.
Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data form a phase III randomized trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11:21–8.
Mehra R, Seiwer TY, Gupta S, Weiss J, Gluck I, Eder JP, et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer. 2018;119:153–9.
Yue Q, Zhang M, Chen Y, Zheng D, Chen Y, Feng M. Establishment of prognostic factors in recurrent nasopharyngeal carcinoma patients who received salvage intensity-modulated radiotherapy: a meta-analysis. Oral Oncol. 2018;81:81–8.
Solomon B, Young RJ, Rischin D. Head and neck squamous cell carcinoma: genomics and emerging biomarkers for immunomodulatory cancer treatments. Semin Cancer Biol. 2018; https://doi.org/10.1016/j.semcancer.2018.01.008. [Epub ahead of print].
Bonner JA, Mesia R, Giralt J, Psyrri A, Keilholz U, Rosenthal DI, et al. p19, HPV, and cetuximab: what is the evidence? Oncologist. 2017;22:811–22.
Smith IE, Harrris AL, Morgan M, Ford HT, Gazet JC, Harmer CL, et al. Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. Br Med J (Clin Res Ed). 1981;283:1432–4.
International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature. 2001;409:860–921.
Shendure J, Hanlee J. Next-generation DNA sequencing. Nat Biotechnol. 2008;26:1135–45.
Broach JR, Thorner J. High-throughput screening for drug discovery. Nature. 1996;384(Suppl):14–6.
Drucker BJ, Guilhot F, O’Brien SG, Gatmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–17.
Eggermont AMM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer. 2004;40:1825–36.
McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15:323–32.
Shak S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin Oncol. 1999;26(Suppl 12):71–7.
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84.
Cheung MC, Haynes AE, Meyer RM, Stevens A, Imrie KR, Members of the Hematology, Disease Site Group of the Cancer Care Ontario Program in Evidence-Based Care. Rituximab in lymphoma: a systematic review and consensus practice guidelines for cancer care Ontario. Cancer Treat Rev. 2007;33:161–76.
Fabi A, De Laurentiis M, Caruso M, Valle E, Moscetti L, Santini D, et al. Efficacy and safety of T-DM1 in the ‘common-practice’ of HER2+ advanced breast cancer setting: a multicenter study. Oncotarget. 2017;8:6481–9.
Mondello P, Cuzzocrea S, Navarra M, Mian M. 90 Y-ibritumomab tiuxetan: a nearly forgotten opportunity. Oncotarget. 2016;7:7597–609.
Keating GM. Bevacizumab: a review of its use in advanced cancer. Drugs. 2014;74:1891–925.
Acúrcio RC, Scomparin A, Conniot J, Salvador JAR, Satchi-Fainaro R, Florindo HF, Cardos Guedes R. Structure-function analysis of immune checkpoint receptors to guide emerging anticancer immunotherapy. J Med Chem. 2018; https://doi.org/10.1021/acs.jmedchem.8b00541. [Epub ahead of print].
Mahoney KM, Freeman GJ, McDermott DF. The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin Ther. 2015;37:764–82.
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.
Menaria J, Kitawat S, Verma V. Cancer vaccine: an overview. SJAMS. 2013;1:161–71.
Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cell for acute lymphoid leukaemia. N Engl J Med. 2013;368:1509–18.
Ramos CA, Heslop HE, Brenner MK. CAR-T cell therapy for lymphoma. Annu Rev Med. 2016;67:165–83.
The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med. 1991;324:1685–90.
Pignon JP, le Maitre A, Maillard E, Bourhis J, Group M-NC. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92:4–14.
Ribassin-Majed L, Marguet S, Lee AWM, Ng WT, Ma J, Chan ATC, et al. What is the best treatment in nasopharyngeal carcinoma? An individual patient data network meta-analysis. J Clin Oncol. 2016;35:498–505.
Vishak S, Rangarajan B, Kekatpure VD. Neoadjuvant chemotherapy in oral cancers: selecting the right patients. Indian J Med Paediatr Oncol. 2015;36:148–53.
Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357:1705–15.
Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357:1695–704.
Camille N, Rozehnal J, Roy E, Uczkowski D, Olson A, Genden E, et al. A phase I study of cabazitaxel in combination with platinum and 5-fluorouracil (PF) in locally advanced squamous cell carcinoma of head and neck (LA-SCCHN). Oral Oncol. 2017;71:99–104.
Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, et al. Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. J Clin Oncol. 2014;32:2735–43.
Haddad R, O’Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013;14:257–64.
Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire E, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomised phase II study. J Clin Oncol. 2013;31:853–9.
Vermorken JB, Mesia R, Rivera F, Remenar E, Kaewecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–27.
Chang PM, Lu HJ, Wang LW, Tai SK, Chen MH, Chu PY, et al. Effectiveness of incorporating cetuximab into docetaxel/cisplatin/fluorouracil induction chemotherapy and chemoradiotherapy for inoperable squamous cell carcinoma of the oral cavity: a phase II study. Head Neck. 2017;39:1333–42.
Specenier PM, Remenar E, Buter J, Schriivers DL, Bergamini C, Licitra LF, et al. TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial. Ann Oncol. 2017;28:2219–24.
Bauml J, Selwert TY, Pfister F, Worden F, Liu J, Gilbert J, et al. Pembrolizumab for platinum—and cetuximab-refractory head and neck cancer: results from a single-arm phase II study. J Clin Oncol. 2017;35:1542–9.
Šeparovic R, Pavlovic M, Silovski T, Tecic Vuger M, Juric A. Systemic therapy of head and neck carcinoma. Lib Oncol. 2016;44:45–9.
Juloori A, Koyfman SA, Geiger JL, Joshi NP, Woody NM, Burkey BB, et al. Definitive chemoradiation in locally advanced squamous cell carcinoma of the hypopharynx: long-term outcomes and toxicity. Anticancer Res. 2018;38:3543–9.
Lee SY, Choi YS, Song I-C, Park SJ, Keam B, Yang YJ, et al. Comparison of standard-dose 3-weekly cisplatin for concurrent chemoradiation of patients with locally advanced head and neck squamous cell cancer: a multicentre retrospective analysis. Medicine. 2018;97:810778. https://doi.org/10.1097/MD.0000000000010778.
Rades D, Seidl D, Janssen S, Bajrovic A, Hakim SG, Wollenberg B, Schild SE. Do we need 5-FU in addition to cisplatin for chemoradiation of locally advanced head- and-neck cancer? Oral Oncol. 2016a;57:40–5.
Rades S, Strojan P, Sedl D, Janssen S, Bajorvic A, Kazic N, et al. Radiochemotherapy for locally advanced squamous cell carcinoma of the head and neck: higher-dose cisplatin every 3 weeks versus cisplatin/5-fluorouracil every 4 weeks. J Craniomaxillofac Surg. 2016b;44:1436–40.
Nagasaka M, Zak M, Issa M, Kim H, Abrams J, Sukari A. Definitive chemoradiotherapy with carboplatin for squamous cell carcinoma of the head and neck. Laryngoscope. 2017;127:2260–4.
Nakahara S, Hanamoto A, Seo Y, Miyaguchi S, Yamaoto Y, Tomiyama Y, et al. Chemoradiotherapy with weekly low-dose docetaxel and cisplatin concurrent with radiation for patients with locally advanced nasopharyngeal carcinoma, followed by adjuvant chemotherapy for selected patients. Jpn J Clin Oncol. 2016;46:903–10.
Mitsudo K, Toshiyuki K, Iida M, Iwai T, Nakashima H, Oguri S, et al. Retrograde superselective intra-arterial chemotherapy and daily concurrent radiotherapy for stage III and IV oral cancer: analysis of therapeutic results in 112 cases. Radiother Oncol. 2014;111:306–10.
Geoffrois L, Martin L, De Raucourt D, Sun XS, Tao Y, Maingon P, et al. Induction chemotherapy followed by cetuximab radiotherapy is not superior to concurrent chemoradiotherapy for head and neck carcinomas: results of the GORTEC 2007-02 Phase III randomized trial. J Clin Oncol. 2018; https://doi.org/10.1200/JCO.2017.76.2591. [Epub before print].
Barney CL, Walson S, Zamora P, Healy EH, Nolan N, Diavolitsis VM, et al. Clinical outcomes and prognostic factors in cisplatin versus cetuximab chemoradiation for locally advanced p16 positive oropharyngeal carcinoma. Oral Oncol. 2018;79:9–14.
Rischin D, Peters LJ, O’Sullivan B, Giralt J, Fisher R, Yuen K, et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART0): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol. 2010;28:2989–95.
Iocca O, Farcomeni A, Di Rocco A, Di Maio P, Golusinski P, Pardinas Lopez S, et al. Locally advanced squamous cell carcinoma of the head and neck: a systematic review and Bayesian network meta-analysis of the currently available treatment options. Oral Oncol. 2018;80:40–51.
Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefevbre JL, Greiner RH, et al. Post-operative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945–52.
Cooper JS, Pajak TF, Forastierre AA, Jacobs J, Campbell BH, Saxsman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937–44.
Cooper JS, Zhang Q, Pajak TF, Forastierre AA, Jacobs J, Saxman SB, et al. Long-term follow-up of the RTOG 9501/Intergroup phase II trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2012;84:1198–205.
Kirke DN, Qureshi MM, Kamran SC, Ezzat W, Jalisi S, Salama A, et al. Role of adjuvant chemoradiotherapy in T4N0 stage IV head and neck cancer: a national Cancer Database analysis. Head Neck. 2018;40:1174–84.
Franchin G, Minatel E, Politi D, Gobitti C, Talamini R, Vaccher E, et al. Postoperative reduced dose of cisplatin concomitant with radiation therapy in high-risk head and neck squamous cell carcinoma. Cancer. 2009;115:2464–71.
Harari PM, Harris J, Kies MS, Myers JN, Jordan RC, Gillison ML, et al. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. J Clin Oncol. 2014;32:2486–95.
Araki D, Redman MW, Martins R, Eaton K, Baik C, Chow L, et al. Concurrent cetuximab and postoperative radiation in resected high-risk squamous cell carcinomas of the head and neck: a single-institution experience. Head Neck. 2016;38:1318–23.
Harrington K, Temam S, Mehanna H, D’Cruz A, Jain M, D’onofrio I, et al. Postoperative adjuvant lapatinib and concurrent chemoradiotherapy followed by maintenance lapatinib monotherapy in high-risk patients with resected squamous cell carcinoma of the head and neck: a phase III, randomized, double-blind, placebo-controlled study. J Clin Oncol. 2015;33:4202–9.
Tam M, Wu SP, Gerber NK, Lee A, Schreiber D, Givi B, Hu K. The impact of adjuvant chemoradiotherapy timing on survival of head and neck cancers. Laryngoscope. 2018; https://doi.org/10.1002/lary.27.152. [Epub before print].
Zenga J, Gross J, Fowler S, Chen J, Vila P, Richmon JD, et al. Salvage of recurrence after surgery and adjuvant therapy: a systematic review. Am J Otolaryngol. 2018;39:223–7.
Civantos FJ, Karakullukcu B, Biel M, Silver CE, Rinaldo A, Saba NF, et al. A review of photodynamic therapy for neoplasms of the head and neck. Adv Ther. 2018;35:324–40.
Vander Poorten V, Meulemans J, Nuyts S, Clement P, Hermans R, Hauben E, Delaere P. Postoperative photodynamic therapy as a new adjuvant treatment after robot-assisted salvage surgery of recurrent squamous cell carcinoma of the base of tongue. World J Surg Oncol. 2015;13:214–8.
Spencer SA, Harris J, Wheeler RH, Machtay M, Schultz C, Spanos W, et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck. 2008;30:21–8.
Morton RP, Rugman F, Dorman EB, Stoney PJ, Wilson JA, McCormick M, et al. Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial. Cancer Chemother Pharmacol. 1985;15:283–9.
Eisenberger M, Hornedo J, Silva H, Donehower R, Spaulding M, Van Echo D. Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol. 1986;4:1506–9.
Sharma M, Gupta M, Fotedar V, Sharma A. Methotrexate, an attractive agent for palliation in head and neck cancers. South Asian J Cancer. 2014;3:299.
Jacobs C, Lyman G, Velez-Garcai E, Sridhar KS, Knight W, Hochster H, et al. A phase II randomised study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992;10:257–63.
Dreyfus AI, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM, et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol. 1996;14:1672–8.
Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, et al. Randomised phase II evaluation of cisplatin plus fluorouracil versus cisplatin in advanced head and neck cancer (E1359): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;20:3562–7.
Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA, Eastern Cooperative Oncology Group. Phase III randomised trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005;23:8646–54.
Vermorken JB, Stöhlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECRUM): an open-label phase 3 randomised trial. Lancet Oncol. 2013;14:697–710.
Machiels JP, Subramanian S, Ruzsa A, Repassy G, Lifirenko I, Flyglare A, et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol. 2011;12:333–43.
Jimenca A, Machiels JP, Wirth L, Specenier P, Seiwert TY, Mardiuadi F, et al. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluoruracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck. Cancer. 2016;122:3803–11.
Siu LL, Soulieres D, Chen EX, Pond GR, Chin SF, Francis P, et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. A Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Trials Group Study. J Clin Oncol. 2007;25:2178–83.
Argiris A, Karamouzis MV, Gooding WE, Bransletter BF, Zhong S, Raez LE, et al. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol. 2011;29:1140–5.
Fury MG, Lee NY, Sherman E, Ho AL, Rao S, Heguy A, et al. A phase I study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2013;87:479–86.
Dunn LA, Fury MG, Xiao H, Baxi SS, Sherman EJ, Korte S, et al. A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Ann Oncol. 2017;28:2533–8.
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856–67.
Gillison ML, Blumenschein GR, Fayette J, Guijay J, Coeva AD, Licitra L, et al. CheckMate 141: 1-year update and subgroup analysis of nivolumab as first-line therapy in patients with recurrent/metastatic head and neck cancer. Oncologist. 2018; https://doi.org/10.1634/theoncologist.2017-0674.
Chow LQ, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, et al. Antitumour activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol. 2016;34:3838–45.
Cohen EE, Harrington KJ, Le Tourneau C, Dinis J, Licitra L, Ahn M-J, et al. Pembrolizumab (pembo) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): phase III KEYNOTE-040 trial. Ann Oncol. 2017;28(Suppl 5) https://doi.org/10.1093/annonc/mdx440.040.
Dietsch GN. Motolimod effectively drives immune function activation in advanced cancer patients. Oncoimmunology. 2016; https://doi.org/10.1080/2162402X.2015.1126037.
Ferris RL, Saba NF, Gitilitz BJ, Haddad R, Sukari A, Neupane P, et al. Effect of adding motolimod to standard combination chemotherapy and cetuximab treatment of patients with squamous cell carcinoma of the head and neck: The active8 randomised clinical trial. JAMA Oncol. 2018; https://doi.org/10.1001/jamaoncol.2018.1888. [Epub before print].
Specenier P, Vermorken JB. Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma. Expert Rev Anticancer Ther. 2018; https://doi.org/10.1080/14737140.2018.1493925.
Stewat JS, Cohen EE, Licitra L, Van Herpen CM, Khorprasert C, Soulieres D, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol. 2009;27:1864–71.